- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Alembic Pharma's Q2 saw revenue up 16% to ₹1,910 Cr and PAT up 20% to ₹185 Cr. EBITDA rose 26% to ₹325 Cr. Strong growth across US Generics (+21%) and Ex-US International (+31%). Acquired Utility Therapeutics for US branded drug entry.